PediCAP

Authors: Kiggwe A, Nalwanga D, Tagoola A, Madhi S, Moore PD, Archary M, Mulenga V, Mujuru AH, Sacarlal J, Buck WC, Sidat M, Nguyen H, Haque F, Dennis E, Clements M, Murphy B, Spittle B, Viero F, Bielicki J, Musiime V,  Sharland M

Presented at: The EDCTP Forum 2023

Authors: Pillay K, Archary M, Bielicki J, Buck WC, Clements M, Dennis E, Goelen J, Haque F, Kiggwe A, Madhi S, Moore PD, Mujuru AH, Mulenga V, Murphy B, Musiime V, Nalwanga D, Nguyen H, Sacarlal J, Sidat M, Spittle B, Tagoola A, Viero F, Sharland M

Presented at: The EDCTP Forum 2023

Authors: Sacarlal WJ, Buck C, Passanduca A, Macassa E, Saíde A, Chhaganlal K, Gafur M, Seni A, Machava S, Martins L, Issa F, Macanze E, Manjate N, Chaúque S, Langa S, Sidat M, Cassia U, Salimo A, Mavume C, Massitela C, Maieca A, Joaquim W, Martins S, Adriano Q, Zandamela M, Bramugy J, Bassat Q, Moraleda C, Tagarro A, Sharland M, Rojo P

Presented at: The EDCTP Forum 2023

Authors: Moore PD, Waggie Z, Nkosi S, Nkosi L, Kumalo N, Nkumana N, Zulu N, Dangor Z, Sharland M, Madhi S

Presented at: The EDCTP Forum 2023

The PediCAP team is pleased to report that the 1100 patients required for the main trial in this study have now been recruited.

PediCAP is an innovative, EDCTP funded clinical trial, using a novel durations design led by the MRC Clinical Trials Unit that is studying the optimal drug, dose and duration of oral step-down antibiotics for children admitted to hospital with severe community-acquired pneumonia.  

We are pleased to announce that the PediCAP trial have successfully passed its 25% recruitment milestone with more than 400 patients successfully randomised into their arms. PediCAP will determine whether children hospitalised for severe or very severe pneumonia, do better on co-amoxiclav or amoxicillin oral step-down therapy and how long these children should continue to receive antibiotic treatment.

Currently, the WHO recommends that children with severe or very severe pneumonia receive injectable antibiotics for at least five days as these antibiotics cover a wide range of bacterial pathogens than oral amoxicillin alone.

At the end of 2021, LAB-Net provided training on the sampling and microbiology procedures to all five sites taking part in the microbiology sub-study in the Paediatric Community Acquired Pneumonia (PediCAP) project.  

Microbiologists, technicians and study investigators from local teams in South Africa, Uganda, Zambia and Zimbabwe attended online training sessions conducted in November and December.

It’s impossible to ignore the Covid-19 pandemic and how it has gripped the lives of everyone around the world, but it is equally impossible to ignore the thousands of lives that are lost daily to chest infections (pneumonia). According to UNICEF, pneumonia is the single largest cause of death in children under five and the majority of these deaths occur in low- and middle-income countries.

Pneumonia needn’t be the deadly infectious disease that it is today.

We are proud to announce that on the 7th of December 2020, the PediCAP team at Makerere University at the China-Uganda Friendship Hospital Naguru (Kampala, Uganda) recruited the very first participant into the PediCAP clinical trial.

Though the study experienced a delayed start due to the COVID-19 pandemic, the drive and commitment of the Ugandan team ensured all ethical and regulatory approvals were acquired by June 2020,

We are pleased to announce the launch of the brand new PediCAP project website!

Take a look at this new website, which describes the background, goals and the different activities foreseen in the PediCAP project, as well as an overview of the project consortium.

The colorful style and the structure are similar to other projects websites created by Penta, such as Odyssey and REACH,